PARTNERSHIPS

Hims Writes Its Biggest Check Yet

Hims & Hers acquired Australian telehealth firm Eucalyptus for $240M upfront, unlocking Asia-Pacific markets in Q1 2026's biggest health-tech deal

23 Jun 2026

Hims and Hers IPO banner on the New York Stock Exchange with American flags and a pedestrian in the foreground

American digital health firms have tried organic growth in Asia-Pacific before. They planted flags, watched them fall, and retreated. Hims & Hers, the New York-listed telehealth platform known for hair loss tablets and weight-loss drugs, is betting that buying its way in will work where building could not.

On March 1st the company closed a $240m acquisition of Eucalyptus, an Australian telehealth operator with consumer brands and regulatory footholds across the region. Earn-out clauses could push the total to $1.15bn. Industry analyst Halle Tecco was direct: "This was the quarter's largest M&A deal by far."

The logic is straightforward. Eucalyptus brings patient networks, local brand equity, and relationships with regulators that Hims could not have assembled quickly on its own. Asia-Pacific telehealth is growing fast, driven by smartphone adoption and shifting expectations around on-demand medical care. American platforms have long struggled to translate domestic models into markets where regulatory norms and cultural preferences differ sharply. Eucalyptus sidesteps that problem by already being local.

Broader forces are at work too. Investor patience with digital health's burn-and-grow era has shortened. Platforms that can demonstrate scale and a path to profit have become acquisition targets; those without one have become warnings. Consolidation is accelerating. Hims, with a profitable core business and appetite for geographic diversification, is acting before valuations climb further.

What this means for consumers is less obvious. Competition could broaden access to telehealth services across Australia and neighbouring markets. Pressure on adjacent health businesses will rise. Whether a platform built on American consumer habits can serve Asian markets without friction is a question the deal's earnout structure implicitly raises. Paying full price takes time.

Related News

topics on the agenda

FROM SYMPTOM TO SOLUTION: WINNING THE NEW PATIENT JOURNEY

Day 1: WEDNESDAY, JULY 8, 2026

09:00 - 09:25

TELEHEALTH UNDER SCRUTINY: PERSPECTIVES FROM HEALTHCARE AND WHITE-COLLAR COUNSEL ON SURVIVING UPIC AUDITS AND DOJ INVESTIGATIONS

Day 1: WEDNESDAY, JULY 8, 2026

09:30 - 09:55

PANEL DISCUSSION ON INNOVATIONS AND CHALLENGES IN REMOTE PATIENT MONITORING AND PERSONALIZED CARE

Day 1: WEDNESDAY, JULY 8, 2026

11:00 - 11:30

View more topics

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.